Back to top
more

Merck & Co. (MRK)

(Delayed Data from NYSE)

$113.69 USD

113.69
11,809,273

+0.60 (0.53%)

Updated Sep 27, 2024 04:00 PM ET

After-Market: $113.60 -0.09 (-0.08%) 7:24 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (60 out of 251)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Here's How J&J (JNJ) Will Roll Out Drug Sector Q3 Earnings

J&J's (JNJ) Pharma segment is expected to have performed above market while the Medical Devices segment might have been hurt by the COVID-19 impact in the third quarter.

Merck (MRK) Gains But Lags Market: What You Should Know

Merck (MRK) closed the most recent trading day at $80.04, moving +0.51% from the previous trading session.

Sweta Killa headshot

Here's Why Small-Cap ETFs Are Hitting New Highs

Small-Cap ETFs hit new highs in the recent trading session. We have highlighted some solid reasons for their strong performance.

3 Top-Ranked Dividend Stocks: A Smarter Way to Boost Your Retirement Income - October 07, 2020

The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?

Bristol Myers' Opdivo & Yervoy Win FDA Nod for Mesothelioma

Bristol Myers' (BMY) Opdivo in combination with Yervoy gets an FDA approval for malignant pleural mesothelioma.

Why the Earnings Surprise Streak Could Continue for Merck (MRK)

Merck (MRK) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Merck Banks on Keytruda, Pipeline & Deals Amid Generic Woes

Keytruda, approved for several types of cancer, alone accounts for more than 25% of Merck's (MRK) pharmaceutical sales Animal health and vaccine products remain core growth drivers.

The Zacks Analyst Blog Highlights: Alibaba, UnitedHealth, Merck & Co., Chipotle Mexican Grill and IDEXX Laboratories

The Zacks Analyst Blog Highlights: Alibaba, UnitedHealth, Merck & Co., Chipotle Mexican Grill and IDEXX Laboratories

J&J Simponi Aria Gets FDA Nod for Pediatric Use in Arthritis

FDA approves J&J's (JNJ) Simponi Aria for the treatment of polyarticular juvenile idiopathic arthritis (pJIA) and juvenile psoriatic arthritis (jPsA) in patients two years of age and older.

Sheraz Mian headshot

Top Analyst Reports for Alibaba, UnitedHealth & Merck

Today's Research Daily features new research reports on 16 major stocks, including Alibaba Group (BABA), UnitedHealth Group (UNH) and Merck (MRK).

Merck (MRK) Outpaces Stock Market Gains: What You Should Know

In the latest trading session, Merck (MRK) closed at $82.95, marking a +1.28% move from the previous day.

Celyad-Merck Team Up to Evaluate CYAD-101 in Colorectal Cancer

Celyad Oncology (CYAD) collaborates with Merck to evaluate its CAR-T candidate, CYAD-101,combined with the latter's Keytruda in microsatellite stable refractory metastatic colorectal cancer.

Eiger Down on Disappointing Results From Coronavirus Study

Eiger (EIGR) declines on disappointing study results on candidate, peginterferon lambda-1a (lambda), in outpatients with mild and uncomplicated COVID-19.

Why Merck (MRK) is a Great Dividend Stock Right Now

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Merck (MRK) have what it takes? Let's find out.

Bristol-Myers' Opdivo Meets Goals in Bladder Cancer Study

Bristol-Myers' (BMY) Opdivo meets primary endpoint in a phase III study in patients with urothelial carcinoma.

Kinjel Shah headshot

Pharma Stock Roundup: J&J's Coronavirus Vaccine in Phase III, Other Updates

J&J (JNJ) becomes the fourth company to start a phase III study on its coronavirus vaccine candidate. CHMP recommends approval of several drugs.

Merck (MRK) Stock Moves -0.37%: What You Should Know

In the latest trading session, Merck (MRK) closed at $82.63, marking a -0.37% move from the previous day.

Glaxo's Zejula Gets Positive CHMP View for First-Line Setting

The CHMP's favorable response recommends the regulatory nod for GlaxoSmithKline's (GSK) Zejula as the first-line maintenance treatment of ovarian cancer patients regardless of the biomarker status.

Seattle Genetics' Padcev Study Aids Urothelial Cancer Survival

Seattle Genetics' (SGEN) phase III EV-301 study on Padcev meets the main goal of overall survival compared to chemotherapy in patients previously treated for locally advanced/metastatic urothelial cancer.

Kinjel Shah headshot

Pharma Stock Roundup: AZN, LLY & PFE's Coronavirus Updates, MRK's New Cancer Deals

AstraZeneca (AZN) resumes its coronavirus vaccine study in the United Kingdom. Merck (MRK) inks two oncology deals with Seattle Genetics.

Corcept's Lead Drug Korlym Aids Growth, Heavy Reliance a Woe

Corcept's (CORT) Cushing's syndrome drug Korlym shows a steady progress. Other pipeline candidates are advancing as well. However, heavy dependence on Korlym for growth remains an overhang.

Bristol-Myers' Opdivo+Yevroy Application Gets EMA Validation

Bristol Myers Squibb (BMY) gets EMA validation for a type II variation application for its Opdivo+Yervoy combination to treat previously untreated, unresectable malignant pleural mesothelioma.

Lilly Drug Gets Fast Track to Improve Heart Attack Outcome

Lilly's (LLY) EMPACT-MI study is part of Jardiance's ENPOWER clinical program, which is studying the impact of Jardiance on major clinical cardiovascular and renal outcomes in a spectrum of cardio-renal-metabolic conditions.

Merck (MRK) Gains But Lags Market: What You Should Know

Merck (MRK) closed the most recent trading day at $84.21, moving +0.06% from the previous trading session.

Seattle Genetics Up on Two New Oncology Deals With Merck

Seattle Genetics (SGEN) strikes a couple of deals with Merck to co-develop ladiratuzumab vedotin for breast cancer and other solid tumors. Also, Merck will market the company's Tukysa in some places.